<DOC>
	<DOCNO>NCT00922584</DOCNO>
	<brief_summary>This trial 's aim evaluate efficacy toxicity sorafenib relapse advanced Non-Small Cell Lung Cancer ( NSCLC ) failure epidermal growth factor receptors-tyrosine kinase inhibitor ( EGFR-TKI ) treatment explore correlation clinical outcome biochemical modulation signal transduction pathway .</brief_summary>
	<brief_title>Sorafenib Treatment Non-Small Cell Lung Cancer After Failure Epidermal Growth Factor Receptor-tyrosine Kinase Inhibitor</brief_title>
	<detailed_description>Sorafenib , oral multi-kinase inhibitor , target Raf/MEK/ERK pathway level Raf kinase VEGF receptor tyrosine kinase , show efficacy NSCLC Phase I/II trial . Because target sorafenib different EGFR-TKI , reasonable sorafenib treat relapse advanced NSCLC failure EGFR-TKI treatment .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Histological cytological document stage IIIB ( amenable radical regional therapy ) stage IV NSCLC . The pathological diagnosis must adenocarcinoma without bronchioalveolar carcinoma . Sputum cytology alone exclude . Recurrent progressive disease prior one EGFRTKI treatment . The patient must stop EGFRTKI treatment least two week . The response EGFRTKI partial response complete response stable disease ( duration stable disease 3 month ) . Patients never receive chemotherapy receive one regimen chemotherapy EGFRTKI eligible . Prior surgery , include palliative surgery , permit perform 4 week start study treatment patient fully recover . Prior localize radiotherapy 4 week start study permit administered target lesion select study , unless progression select target lesion within radiation portal document . Patient recover CTCAE grade 3/4 toxicity radiotherapy . Palliative radiotherapy within 4 week start study also permit . Age &gt; 18 year . ECOG Performance Status 0 , 1 , 2 . Life expectancy least 3 month . Measurable disease , accord RECIST , presence least one unidimensional measurable lesion long diameter &gt; 20 mm conventional technique &gt; 10 mm spiral CT scan . Adequate bone marrow , liver renal function assess follow laboratory requirement conduct within 7 day prior screen : Hemoglobin &gt; 9.0 g/dl Platelet count &gt; 75x109/L Total bilirubin ≤ 1.5 x upper limit normal ALT AST &lt; 2.5 x upper limit normal without liver metastasis , ALT AST &lt; 5 x upper limit normal liver metastasis . International normalized ratio ( INR ) ≤ 1.5 x upper limit normal prothrombin time ( PT ) ≤ 1.5 x upper limit normal . Patients therapeutically anticoagulated agent Coumadin heparin allow participate provide prior evidence underlie abnormality parameter exist . Serum creatinine &lt; 1.5 x upper limit normal . Patients currently enrol , eligible , access , sorafenib clinical trial . Mixed small cell nonsmall cell lung cancer histology . Other pathological type NSCLC adenocarcinoma bronchioloalveolar cell carcinoma . Failure EGFRTKI due toxicity . Prior exposure biotherapy , immunotherapy within 4 week study entry . Prior exposure sorafenib agent target Ras/MARK pathway VEGFR . Any unresolved toxicity CTCAE grade 2 previous anticancer therapy . Patients cardiac arrhythmias great grade 1 NCI CTCAE , Version 3.0 ( Conduction abnormality supraventricular arrhythmia present patient asymptomatic ; intervention indicate , palpitation present QTC &gt; 0.450.47 second ) ; however , patient grade 2 atrial fibrillation may include . Significant cardiovascular event : congestive heart failure &gt; NYHA class 2 ; unstable angina , active CAD ( myocardial infarction 6 month prior study entry allow ) ; serious cardiac arrhythmia require antiarrythmic therapy ( beta blocker digoxin permit ) uncontrolled hypertension . Any disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use study medication ( sorafenib ) might affect interpretation result render subject high risk treatment . Central nervous system ( CNS ) tumor metastatic tumor . Clinically significant gastrointestinal bleeding within 30 day study entry .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2013</verification_date>
	<keyword>non-small cell lung cancer</keyword>
	<keyword>Sorafenib</keyword>
	<keyword>target therapy</keyword>
</DOC>